Minoxidil
Tablet · Topical, Oral
Uses
Because of the potential for serious adverse effects, minoxidil tablets are indicated only in the treatment of hypertension that is symptomatic or associated with target organ damage and is not manageable with maximum therapeutic doses of a diuretic plus two other antihypertensive drugs. At the present time use in milder degrees of hypertension is not recommended because the benefit-risk relationship in such patients has not been defined. Minoxidil reduced supine diastolic blood pressure by 20 mmHg or to 90 mmHg or less in approximately 75% of patients, most of who had hypertension that could not be controlled by other drugs.
Warnings
1. Salt and Water Retention: Congestive Heart Failure - concomitant use of an adequate diuretic is required - Minoxidil tablets must usually be administered concomitantly with a diuretic adequate to prevent fluid retention and possible congestive heart failure; a high ceiling (loop) diuretic is almost always required. Body weight should be monitored closely. If minoxidil is used without a diuretic, retention of several hundred milli-equivalents of salt and corresponding volumes of water can occur within a few days, leading to increased plasma and interstitial fluid volume and local or generalized edema. Diuretic treatment alone, or in combination with restricted salt intake, will usually minimize fluid retention, although reversible edema did develop in approximately 10% of nondialysis patients so treated. Ascites has also been reported. Diuretic effectiveness was limited mostly by disease-related impaired renal function. The condition of patients with pre-existing congestive heart failure occasionally deteriorated in association with fluid retention although because of the fall in blood pressure (reduction of afterload), more than twice as many improved than worsened. Rarely, refractory fluid retention may require discontinuation of minoxidil. Provided that the patient is under close medical supervision, it may be possible to resolve refractory salt retention by discontinuing minoxidil for 1 or 2 days and then resuming treatment in conjunction with vigorous diuretic therapy. 2. Concomitant Treatment to Prevent Tachycardia is Usually Required - Minoxidil increases the heart rate. Angina may worsen or appear for the first time during minoxidil treatment, probably because of the increased oxygen demands associated with increased heart rate and cardiac output. The increase in rate and the occurrence of angina generally can be prevented by the concomitant administration of a beta-adrenergic blocking drug or other sympathetic nervous system suppressant. The ability of beta-adrenergic blocking agents to minimize papillary muscle lesions in animals is further reason to utilize such an agent concomitantly. Round-the-clock effectiveness of the sympathetic suppressant should be ensured. 3. Pericarditis, Pericardial Effusion and Tamponade - There have been reports of pericarditis occurring in association with the use of minoxidil. The relationship of this association to renal status is uncertain. Pericardial effusion, occasionally with tamponade, has been observed in about 3% of treated patients not on dialysis, especially those with inadequate or compromised renal function. Although in many cases, the pericardial effusion was associated with a connective tissue disease, the uremic syndrome, congestive heart failure, or marked fluid retention, there have been instances in which these potential causes of effusion were not present. Patients should be observed closely for any suggestion of a pericardial disorder, and echocardiographic studies should be carried out if suspicion arises. More vigorous diuretic therapy, dialysis, pericardiocentesis, or surgery may be required. If the effusion persists, withdrawal of minoxidil should be considered in light of other means of controlling the hypertension and the patient’s clinical status. 4. Interaction with Guanethidine: Although minoxidil does not itself cause orthostatic hypotension, its administration to patients already receiving guanethidine can result in profound orthostatic effects. If at all possible, guanethidine should be discontinued well before minoxidil is begun. Where this is not possible, minoxidil therapy should be started in the hospital and the patient should remain institutionalized until severe orthostatic effects are no longer present or the patient has learned to avoid activities that provoke them. 5. Hazard of Rapid Control of Blood Pressure: In patients with very severe blood pressure elevation, too rapid control of blood pressure, especially with intravenous agents, can precipitate syncope, cerebrovascular accidents, myocardial infarction and ischemia of special sense organs with resulting decrease or loss of vision or hearing. Patients with compromised circulation or cryoglobulinemia may also suffer ischemic episodes of the affected organs. Although such events have not been unequivocally associated with minoxidil use, total experience is limited at present. Any patient with malignant hypertension should have initial treatment with minoxidil carried out in a hospital setting, both to assure that blood pressure is falling and to assure that it is not falling more rapidly than intended.
Dosage and administration
Patients over 12 years of age: The recommended initial dosage of minoxidil tablets is 5 mg given as a single daily dose. Daily dosage can be increased to 10 mg, 20 mg and then to 40 mg in single or divided doses if required for optimum blood pressure control. The effective dosage range is usually 10 to 40 mg per day. The maximum recommended dosage is 100 mg per day. Patients under 12 years of age: The initial dosage is 0.2 mg/kg minoxidil as a single daily dose. The dosage may be increased in 50 to 100% increments until optimum blood pressure control is achieved. The effective dosage range is usually 0.25 to 1.0 mg/kg/day. The maximum recommended dosage is 50 mg daily ( see 9 . Pediatric Use under PRECAUTIONS ). Dose frequency: The magnitude of within-day fluctuation of arterial pressure during therapy with minoxidil is directly proportional to the extent of pressure reduction. If supine diastolic pressure has been reduced less than 30 mmHg, the drug need be administered only once a day; if supine diastolic pressure has been reduced more than 30 mmHg, the daily dosage should be divided into two equal parts. Frequency of dosage adjustment: Dosage must be titrated carefully according to individual response. Intervals between dosage adjustments normally should be at least 3 days since the full response to a given dose is not obtained for at least that amount of time. Where a more rapid management of hypertension is required, dose adjustments can be made every 6 hours if the patient is carefully monitored. Concomitant therapy: Diuretic and beta-blocker or other sympathetic nervous system suppressant. Diuretics : Minoxidil must be used in conjunction with a diuretic in patients relying on renal function for maintaining salt and water balance. Diuretics have been used at the following dosages when starting therapy with minoxidil: hydrochlorothiazide (50 mg, b.i.d.) or other thiazides at equi-effective dosage; chlorthalidone (50 mg to 100 mg, once daily); furosemide (40 mg, b.i.d.). If excessive salt and water retention results in a weight gain of more than 5 pounds, diuretic therapy should be changed to furosemide; if the patient is already taking furosemide, dosage should be increased in accordance with the patient’s requirements. Beta-blocker or other sympathetic nervous system suppressants: When therapy with minoxidil is begun, the dosage of a beta-adrenergic receptor blocking drug should be the equivalent of 80 mg to 160 mg of propranolol per day in divided doses. If beta-blockers are contraindicated, methyldopa (250 mg to 750 mg, b.i.d.) may be used instead. Methyldopa must be given for at least 24 hours before starting therapy with minoxidil because of the delay in the onset of methyldopa’s action. Limited clinical experience indicates that clonidine may also be used to prevent tachycardia induced by minoxidil; the usual dosage is 0.1 to 0.2 mg twice daily. Sympathetic nervous system suppressants may not completely prevent an increase in heart rate due to minoxidil but usually do prevent tachycardia. Typically, patients receiving a beta-blocker prior to initiation of therapy with minoxidil have a bradycardia and can be expected to have an increase in heart rate toward normal when minoxidil is added. When treatment with minoxidil and beta-blocker or other sympathetic nervous system suppressant are begun simultaneously, their opposing cardiac effects usually nullify each other, leading to little change in heart rate.
Label text from the FDA structured product label by Par Health USA, LLC (revised Jun 11, 2026). Long sections are shortened; the complete label is on DailyMed.
Active ingredients
- Minoxidil in 67 products
Minoxidil NDC products (67)
| NDC | Strength & form | Labeler | Type |
|---|---|---|---|
| 50090-7760 | Minoxidil 10 mg/1 Tablet | A-S Medication Solutions | ANDA |
| 50090-7758 | Minoxidil 2.5 mg/1 Tablet | A-S Medication Solutions | ANDA |
| 0591-5642 | Minoxidil 2.5 mg/1 Tablet | Actavis Pharma, Inc. | ANDA |
| 0591-5643 | Minoxidil 10 mg/1 Tablet | Actavis Pharma, Inc. | ANDA |
| 68084-205 | Minoxidil 10 mg/1 Tablet | American Health Packaging | ANDA |
| 68084-204 | Minoxidil 2.5 mg/1 Tablet | American Health Packaging | ANDA |
| 43353-342 | Minoxidil 2.5 mg/1 Tablet | Aphena Pharma Solutions - Tennessee, LLC | ANDA |
| 42291-618 | Minoxidil 2.5 mg/1 Tablet | AvKARE | ANDA |
| 63629-2231 | Minoxidil 10 mg/1 Tablet | Bryant Ranch Prepack | ANDA |
| 63629-9620 | Minoxidil 10 mg/1 Tablet | Bryant Ranch Prepack | ANDA |
| 63629-9433 | Minoxidil 2.5 mg/1 Tablet | Bryant Ranch Prepack | ANDA |
| 63629-9299 | Minoxidil 10 mg/1 Tablet | Bryant Ranch Prepack | ANDA |
| 63629-2232 | Minoxidil 2.5 mg/1 Tablet | Bryant Ranch Prepack | ANDA |
| 63629-2230 | Minoxidil 10 mg/1 Tablet | Bryant Ranch Prepack | ANDA |
| 71335-3120 | Minoxidil 10 mg/1 Tablet | Bryant Ranch Prepack | ANDA |
| 71335-3174 | Minoxidil 2.5 mg/1 Tablet | Bryant Ranch Prepack | ANDA |
| 72162-1489 | Minoxidil 2.5 mg/1 Tablet | Bryant Ranch Prepack | ANDA |
| 72162-1490 | Minoxidil 10 mg/1 Tablet | Bryant Ranch Prepack | ANDA |
| 63629-1086 | Minoxidil 10 mg/1 Tablet | Bryant Ranch Prepack | ANDA |
| 84382-001 | Minoxidil 50 mg/g Aerosol, Foam | Clarity Cosmetics Inc. | ANDA |
| 51316-213 | Minoxidil 50 mg/g Aerosol, Foam | CVS Pharmacy | ANDA |
| 51316-212 | Minoxidil 50 mg/g Aerosol, Foam | CVS Pharmacy | ANDA |
| 51407-902 | Minoxidil 10 mg/1 Tablet | Golden State Medical Supply, Inc. | ANDA |
| 51407-901 | Minoxidil 2.5 mg/1 Tablet | Golden State Medical Supply, Inc. | ANDA |
| 37808-833 | Minoxidil 5 g/100mL Solution | H E B | ANDA |
| 70550-116 | Minoxidil 50 mg/g Aerosol, Foam | Keranique | ANDA |
| 59450-210 | Minoxidil 50 mg/g Aerosol, Foam | Kroger Company | ANDA |
| 59450-211 | Minoxidil 50 mg/g Aerosol, Foam | Kroger Company | ANDA |
| 0113-5129 | Minoxidil 50 mg/g Aerosol, Foam | L. Perrigo Company | ANDA |
| 68071-3794 | Minoxidil 2.5 mg/1 Tablet | NuCare Pharmaceuticals, Inc. | ANDA |
| 68071-5324 | Minoxidil 2.5 mg/1 Tablet | NuCare Pharmaceuticals, Inc. | ANDA |
| 59726-151 | Minoxidil 50 mg/g Aerosol, Foam | P & L Development, LLC | ANDA |
| 59726-122 | Minoxidil 50 mg/g Aerosol, Foam | P & L Development, LLC | ANDA |
| 59726-116 | Minoxidil 50 mg/g Aerosol, Foam | P & L Development, LLC | ANDA |
| 59726-115 | Minoxidil 50 mg/g Aerosol, Foam | P & L Development, LLC | ANDA |
| 59726-125 | Minoxidil 50 mg/mL Aerosol, Foam | P & L Development, LLC | ANDA |
| 49884-256 | Minoxidil 2.5 mg/1 Tablet | Par Health USA, LLC | ANDA |
| 49884-257 | Minoxidil 10 mg/1 Tablet | Par Health USA, LLC | ANDA |
| 72789-279 | Minoxidil 10 mg/1 Tablet | PD-Rx Pharmaceuticals, Inc. | ANDA |
| 72789-278 | Minoxidil 2.5 mg/1 Tablet | PD-Rx Pharmaceuticals, Inc. | ANDA |
| 68788-8273 | Minoxidil 2.5 mg/1 Tablet | Preferred Pharmaceuticals Inc. | ANDA |
| 70550-605 | Minoxidil 50 mg/g Aerosol, Foam | PROFECTUS BEAUTY LLC | ANDA |
| 82804-240 | Minoxidil 2.5 mg/1 Tablet | Proficient Rx LP | ANDA |
| 71205-757 | Minoxidil 2.5 mg/1 Tablet | Proficient Rx LP | ANDA |
| 56062-070 | Minoxidil 2 g/100mL Solution | Publix Super Markets Inc | ANDA |
| 56062-322 | Minoxidil 5 g/100mL Solution | Publix Super Markets Inc | ANDA |
| 82796-100 | Minoxidil 50 mg/g Aerosol, Foam | RESTORATION HOLDINGS, LLC | ANDA |
| 72484-095 | Minoxidil 5 g/100mL Solution | Roman Health Ventures Inc. | ANDA |
| 72484-097 | Minoxidil 5 g/100mL Spray | Roman Health Ventures Inc. | ANDA |
| 69113-128 | Minoxidil 50 mg/g Aerosol, Foam | SCIENTIFIC HAIR RESEARCH, LLC | ANDA |
| 69113-129 | Minoxidil 50 mg/g Aerosol, Foam | SCIENTIFIC HAIR RESEARCH, LLC | ANDA |
| 82376-6007 | Minoxidil 50 mg/g Aerosol, Foam | SPAZI INC. | ANDA |
| 82376-6006 | Minoxidil 50 mg/g Aerosol, Foam | SPAZI INC. | ANDA |
| 53489-387 | Minoxidil 10 mg/1 Tablet | Sun Pharmaceutical Industries, Inc. | ANDA |
| 53489-386 | Minoxidil 2.5 mg/1 Tablet | Sun Pharmaceutical Industries, Inc. | ANDA |
| 51672-2128 | Minoxidil 50 mg/g Aerosol, Foam | Sun Pharmaceutical Industries, Inc. | ANDA |
| 51672-2129 | Minoxidil 50 mg/g Aerosol, Foam | Sun Pharmaceutical Industries, Inc. | ANDA |
| 11673-157 | Minoxidil 50 mg/g Aerosol, Foam | TARGET Corporation | ANDA |
| 11673-158 | Minoxidil 50 mg/g Aerosol, Foam | TARGET Corporation | ANDA |
| 71713-094 | Minoxidil 5 g/100mL Solution | THIRTY MADISON INC | ANDA |
| 71713-091 | Minoxidil 50 mg/g Aerosol, Foam | Thirty MADISON, Inc. | ANDA |
| 80855-201 | Minoxidil 50 mg/g Aerosol, Foam | Virtue Labs, LLC | ANDA |
| 0363-9091 | Minoxidil 50 mg/g Aerosol, Foam | Walgreen Company | ANDA |
| 0363-9090 | Minoxidil 50 mg/g Aerosol, Foam | Walgreen Company | ANDA |
| 0363-9970 | Minoxidil 2 g/100mL Solution | Walgreens | ANDA |
| 0363-9971 | Minoxidil 50 mg/mL Solution | Walgreens | ANDA |
| 0363-9973 | Minoxidil 50 mg/mL Solution | Walgreens | ANDA |
Frequently asked questions
What is Minoxidil used for?
Because of the potential for serious adverse effects, minoxidil tablets are indicated only in the treatment of hypertension that is symptomatic or associated with target organ damage and is not manageable with maximum therapeutic doses of a diuretic plus two other antihypertensive drugs. At the present time use in milder degrees of hypertension is not recommended because the benefit-risk…
Who makes Minoxidil?
Minoxidil is listed by 32 labelers in the FDA NDC directory, including A-S Medication Solutions, Actavis Pharma, Inc., American Health Packaging, Aphena Pharma Solutions - Tennessee, LLC.